Chris, I'd say that our plans are, we're going to operate as we have been, and we've been a pretty balanced company around deploying capital. We're thrilled with the June quarter the start to the year, $276 million of free cash, and we actually deployed $467 million. So, I'd say, very strong deployment out of the gate. If you look at last 12 months, we generated $1.2 billion of free cash. We deployed about 80% of that, of which three-quarters of that was on repurchase. Now, keep in mind, beginning of the year last year was everyone was hunker down at COVID, so I think 80% is pretty good, all things considered. And then the last eight quarters, we've generated $2 billion of free cash. We've actually deployed $2.1 billion, and 60% of that was repurchased, about 40% -- while 40% was acquisitions. Now, we just got out of the quarter where we -- the ninth quarter was active semi. So if you included that, we actually had deployment of about 50% acquisition, 50% repurchase. So I think we're going to -- the whole management team is focused on long-term free cash flow generation. So we believe we're going to continue to grow free cash flow. We think we will this year. Our priorities, organic investment, continue to have a technology lead. We've got build the capacity we need for the markets that we feel confident about. And then, we look at inorganic opportunities where it makes sense. And we've been fairly active. Of the $1.2 billion that we spent on acquisitions in the last nine quarters, we're really excited about the markets that we have exposure to. We think that we've brought on over $4 billion of TAM with that, that's conservative, and that's excluding Bio. And then several years out, we would see the TAM being north of $10 billion for what we bought. And again, that's excluding Bio, which is an exciting completely new market for Qorvo. So I think we'll continue to look at things that make sense for Qorvo on markets, customers, technology differentiation, financials, of course, and then as we know, culture matters.